Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, Garren H, Maguire R P, Johns DR

J Neurol. 2016 May 3. Epub 2016 May 03. PMID: 27142710. Abstract